Eupraxia Pharmaceuticals Inc. announced updated positive clinical data from its Phase 1b/2a RESOLVE trial, which is evaluating safety and efficacy of EP-104GI as a treatment for eosinophilic Esophagitis ("EoE"). EoE is a life altering, chronic, immune-mediated condition of the esophagus that causes inflammation, structural damage and dysfunction when left untreated.  Patients with EoE experience difficulty and pain in swallowing; the extent of which can dramatically affect their quality of life.  Current treatment options often provide poor or temporary control over the condition and can be accompanied with unpleasant side effects, such as oral fungal infections. The results announced from the second cohort of the RESOLVE trial, using Eupraxia's Diffusphere?

technology for EoE, are derived from a low dose of eight 1 mg injections of EP-104GI administered to a portion of each patient's lower esophagus. There were no serious adverse events or treatment-related adverse events in either cohort. All three of the patients in the second dose cohort showed reductions in their patient-reported outcomes with an average 60% reduction in their Dysphasia Likert score (difficulty swallowing) and an 80% reduction in their Odynophagia Likert score (pain on swallowing) at three months.

Patients demonstrated an average 40% reduction in eosinophil counts at three months in the second cohort. Plasma levels of fluticasone were very low (? 10pg/mL), supporting the potential to increase the dose in future cohorts.

In previous Eupraxia studies, similar plasma levels of fluticasone had no effect on serum cortisol or blood glucose. Patients receiving the very low dose (four 1 mg injections) from the first cohort who reached the six-month mark still reported some beneficial effects from the treatment. The data supports the hypothesis that as the dose increases, the response improves.

The first six patients showed meaningful improvement in self-reported symptoms and pathological findings of the disease assessed by esophageal biopsies. These findings are viewed optimistically in light of the low doses used in the first two cohorts. The Company has previously announced that based on its first external safety review meeting of the RESOLVE trial,the original timeline of the trial was extended to six months to fully characterize the duration of efficacyendpoints.

Durability of response is evidenced by the continued meaningful improvement in symptoms at six months in the first cohort with a low dose, and Eupraxia intends to follow all future cohorts to six months. The third cohort of the RESOLVE trial has been fully recruited and the dosing is five times that of the first cohort (which was four 1 mg injections), with eight 2.5 mg injections offering a higher local dose and a broader spread of drug in the esophagus. The trial's third cohort has now been fully dosed and further results are expected in the second quarter of 2024.